Pharmaceutical Executive March 12, 2025
Partnership includes the development of combination products, including a fixed-dose combination of petrelintide and Roche’s dual GLP-1/GIP receptor agonist, CT-388, for weight management.
Zealand Pharma and Roche have entered into a global collaboration and license agreement worth up to $5.3 billion to co-develop and co-commercialize petrelintide, an amylin analog with best-in-class potential, as a foundational therapy for weight management and other indications. According to the company, the collaboration includes the development of combination products such as a fixed-dose combination of petrelintide and CT-388, Roche’s dual GLP-1/GIP receptor agonist.
Under terms of the deal, Roche will pay Zealand Pharma $1.65 billion upfront, with the potential to receive up to an additional $5.3 billion in milestone payments and sales-based incentives. A total...
Today's Sponsors
Today's Sponsor